Ingredients

Ingredient sets that include moxidectin

Ordered by report count. FDA states that these data "cannot be used to estimate the risk associated with the product or compare one drug or device product with another"; counts follow sales volume and years on the market. A report can list more than one set, so shares can add to more than 100%.

Signs listed in reports, pooled

share of moxidectin reports listing the termall reports in the database

1. Vomiting15.7%15,176
2. Lack of efficacy (endoparasite) - heartworm[the product did not have the expected effect: heartworm]11.1%10,774
3. Lethargy[unusually tired or inactive]9%8,711
4. Diarrhoea[diarrhea]6.4%6,165
5. Lack of efficacy (endoparasite) - hookworm[the product did not have the expected effect: hookworms]5.8%5,586
6. Anaphylaxis[sudden severe allergic-type reaction]5.3%5,114
7. Facial swelling4.8%4,643
8. Pruritus[itching]4.3%4,153
9. Anorexia[not eating]3.9%3,729
10. Lack of efficacy (ectoparasite) - flea[the product did not have the expected effect: fleas]3.6%3,463
11. Hives3.6%3,437
12. Ineffective, heartworm larvae[legacy FDA term: the product did not have the expected effect (heartworm larvae)]3.3%3,199
13. Depression[dull, quiet or withdrawn]3.1%3,037
14. Behavioural disorder NOS[behaviour change, type not specified]3%2,946
15. Ataxia[unsteady, uncoordinated movement]3%2,867
16. Lack of efficacy (endoparasite) - roundworm NOS[the product did not have the expected effect: roundworms]2.8%2,704
17. Death2.8%2,674
18. Seizure NOS[seizure, type not specified]2.5%2,372
19. Hypersalivation[drooling]2.4%2,368
20. Fever2.3%2,241
21. Pale mucous membrane[pale gums]2.1%2,053
22. Urticaria[hives]2.1%2,003
23. Lack of efficacy (endoparasite) - NOS[the product did not have the expected effect: target not specified]1.9%1,827
24. Other abnormal test result NOS[abnormal laboratory result, type not specified]1.9%1,798
25. Death by euthanasia[the animal was euthanized]1.6%1,593
26. Lack of efficacy (endoparasite) - tapeworm[the product did not have the expected effect: tapeworms]1.6%1,557
27. Facial oedema[swollen face]1.6%1,539
28. Weight loss1.6%1,507
29. Panting1.5%1,438
30. Emesis[vomiting]1.4%1,383

Pooled across every ingredient set and every report that names the ingredient. One report can list several terms and several drugs; a term here may relate to any of them or to none.

Monthly reports by species, five years

By month of receipt; each panel has its own scale. The newest months are incomplete because FDA posts reports with a delay of three to six months.

Outcomes, report types and ages

Coloured bar: reports naming moxidectin. Grey bar: all 1,357,245 reports. Outcomes are as stated by the reporter; FDA has not necessarily determined whether any product played a part.

In context

Shares of reports, not of animals treated: how many animals receive the ingredient is not public. Ingredients used in anaesthesia, cancer care or in old animals carry more serious outcomes in their reports for that reason alone.

Where this comes from. Counts are built from the openFDA Animal & Veterinary adverse event bulk files released 28 Sep 2026, which hold reports FDA's Center for Veterinary Medicine received through 31 Mar 2026. openFDA masks brand and manufacturer names in these files, so drugs are counted by the active ingredients each record discloses and no figure is attributed to a brand, application or company. Ingredient names, and the separate reference lists of approved products, follow the FDA Green Book as of 30 Sep 2026. Ingredient names follow the Green Book; salts and forms are kept as FDA lists them. Drug entries are matched by the active ingredients their unmasked ingredient field discloses. No report text, lot numbers or reporter details are published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.